General News | BioCryst Pharmaceuticals, Inc.

Skip to main navigation

Home
News & Events
Press Releases Events & Presentations Media Materials
Stock
Stock Quote & Chart Historic Stock Lookup Analyst Coverage
Corporate Governance
Board of Directors Committee Composition Code of Conduct and Ethics Committee Charters Corporate Responsibility
Finance & Filings
Financial Profile SEC Documents Proxy Online Quarterly Results
Investor Resources
Investor FAQ Email Alerts RSS News Feeds

BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

Read more about BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

Read more about BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

Read more about BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

BioCryst to Present at Rodman & Renshaw Conference

Read more about BioCryst to Present at Rodman & Renshaw Conference

BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

Read more about BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease

Read more about BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease

BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases

Read more about BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases

BioCryst Reports Second Quarter 2014 Financial Results

Read more about BioCryst Reports Second Quarter 2014 Financial Results

BioCryst to Announce Second Quarter 2014 Financial Results August 5

Read more about BioCryst to Announce Second Quarter 2014 Financial Results August 5

BioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering

Read more about BioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering

Pagination

Previous page
Page 49
Next page

Subscribe to General News

Contact Investor Relations

investorrelations@biocryst.com

Investor Tools

Print Page
Printed Materials
Email Alerts
RSS News Feeds
Share Page

© BioCryst Pharmaceuticals, Inc. All Rights Reserved. 2026

Facebook
Twitter
LinkedIn
RSS